Pharmacoeconomic evaluation of warfarin pharmacogenomics

Bibliography

• Loebstein R, Yonath H, Peleg D, Interindividual variability in sensitivity to warfarin – nature or nuture? Clin Pharmacol Ther 2001;70:159-64
   PubMed Web of Science ®Google Scholar
• Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-19
   PubMed Web of Science ®Google Scholar
• Higashi MK, Veenstra DL, Kondo LM, Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287:1690-8
   PubMed Web of Science ®Google Scholar
• Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000;96:1816-19
   PubMed Web of Science ®Google Scholar
• D'Andrea G, D'Ambrosio RL, Di Perna P, A polymorphism in the VKORC1 gene is associated with inter-individual variability in the dose-anticoagulant effect of warfarin. Blood 2005;105:645-9
   PubMed Web of Science ®Google Scholar
• Wadelius M, Chen LY, Downes K, Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005;5:262-70
   PubMed Web of Science ®Google Scholar
• Rieder MJ, Reiner AP, Gage BF, Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352:2285-93
   PubMed Web of Science ®Google Scholar
• Borgiani P, Ciccacci C, Forte V, CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 2009;10:261-6
   PubMed Web of Science ®Google Scholar
• Voora D, Koboldt DC, King CR, A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirement in African Americans. Clin Pharmacol Ther 2010;87:445-51
   PubMed Web of Science ®Google Scholar
• Sconce EA, Khan TI, Wynne HA, The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005;106:2329-33
   PubMed Web of Science ®Google Scholar
• Zhu Y, Shennan M, Reynolds KK, Estimation of warfarin maintenance dose based on VKORC1 (-1639 G > A) and CYP 2C9 genotypes. Clin Chem 2007;53:1199-205
   PubMed Web of Science ®Google Scholar
• Li C, Schwarz UI, Ritchie MD, Relative contribution of CYP 2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood 2009;113:3925-30
   PubMed Web of Science ®Google Scholar
• Carlquist JF, Horne BD, Muhlestein JB, Genotypes of the cytochrome p450 isoform, CYP2C9 and the vitamine K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis 2006;22:191-7
   PubMed Web of Science ®Google Scholar
• Wadelius M, Chen LY, Lindh JD, The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009;113:784-92
   PubMed Web of Science ®Google Scholar
• The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009;360:753-64
   PubMed Web of Science ®Google Scholar
• Wu AHB, Wang P, Smith A, Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 2008;9:169-78
   PubMed Web of Science ®Google Scholar
• Miao L, Yang J. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 2007;63:1135-41
   PubMed Web of Science ®Google Scholar
• Huang SW, Chen HS, Wang XQ, Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics 2009;19:226-34
   PubMed Web of Science ®Google Scholar
• Wen SM, Lee MTM, Chen JJ, Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther 2008;84:83-9
   PubMed Web of Science ®Google Scholar
• You JHS, Wong RSM, Waye MMY, Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. J Thromb Thrombolysis 2010: published online 29 June 2010, doi:10.1007/s11239-010-0497-x
   Google Scholar
• Lenzini PA, Grice CG, Milligan PE, Laboratory and clinical outcomes of pharmacogenetics vs. clinical protocols for warfarin initiation in orthopedic patients. J Thromb Haemost 2008;6:1655-62
   PubMed Web of Science ®Google Scholar
• Ross KA, Bigham AW, Edwards M, Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J Hum Genet 2010: published online 17 June 2010, doi:10.1038/jhg.2010.73
   Google Scholar
• Veenstra DL, You JHS, Rieder MJ, Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics 2005;15:687-91
   PubMed Web of Science ®Google Scholar
• Scott SA, Khasawneh R, Peter I, Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 2010;11:781-91
   PubMed Web of Science ®Google Scholar
• Hillman MA, Wilke RA, Yale SH, A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res 2005;3:137-45
   PubMedGoogle Scholar
• Anderson JL, Horne BD, Stevens SM, Couma-Gen Investigators. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007;116:2563-70
   PubMed Web of Science ®Google Scholar
• Caraco Y, Blotnick S, Muzkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective, randomized, controlled study. Clin Pharmacol Ther 2008;83:460-70
   PubMed Web of Science ®Google Scholar
• Kangelaris KN, Bent S, Nussbaum RL, Genetic testing before anticoagulation? A systematic review of pharmacogenetics dosing of warfarin. J Gen Intern Med 2009;24:656-64
   PubMed Web of Science ®Google Scholar
• Kim MJ, Huang SM, Meyer UA, A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity. J Clin Pharmacol 2009;49:138-46
   PubMed Web of Science ®Google Scholar
• Wadelius M. Use of pharmacogenetics in guiding treatment with warfarin. Clin Chem 2009;55:709-11
   PubMed Web of Science ®Google Scholar
• Rosove MH, Grody WW. Should we be applying warfarin pharmacogenetics to clinical practice? No, not now. Ann Intern Med 2009;151:270-3
   PubMed Web of Science ®Google Scholar
• Eby CS. Pharmacogenetics-based initial dosing of warfarin: not ready for prime time. Clin Chem 2009;55:712-14
   PubMed Web of Science ®Google Scholar
• Clarification of optimal anticoagulation through genetics (COAG). Available from: http://clinicaltrials.gov/ct2/show/NCT00839657 [Last accessed 5 July 2010]
   Google Scholar
• van Schie RMF, Wadelius M, Kamali F, Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 2009;10:1687-95
   PubMed Web of Science ®Google Scholar
• You JHS, Chan FWH, Wong RSM, Cheng G. The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy – a decision analysis. Thromb Haemost 2004;92:590-7
   PubMed Web of Science ®Google Scholar
• Schalekamp T, Boink GJ, Visser LE, CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring? Clin Pharmacol Ther 2006;79:511-20
   PubMed Web of Science ®Google Scholar
• McWilliam A, Lutter R, Nardinelli C. Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarin. Pers Med 2008;5:279-84
   PubMed Web of Science ®Google Scholar
• Eckman MH, Rosand R, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with non-valvular atrial fibrillation. Ann Intern Med 2009;150:73-83
   PubMed Web of Science ®Google Scholar
• You JHS, Tsui KKN, Wong RSM, Cheng G. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients initiating warfarin therapy. Clin Pharmacol Ther 2009;86:540-7
   PubMed Web of Science ®Google Scholar
• Patrick AR, Avorn J, Choudhry NK. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2009: published online 21 July 2009, doi:10.1161/circoutcomes.108.808592
   Google Scholar
• Meckley LM, Gudgeon JM, Anderson JL, A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics 2010;28:61-74
   PubMed Web of Science ®Google Scholar
• Maurice CB, Barua PK, Simses D, Comparison of assay systems for warfarin-related CYP2C9 and VKORC1 genotyping. Clin Chim Acta 2010;411:947-54
   PubMed Web of Science ®Google Scholar